Zai Lab Ltd's stock soared 10.56% during intraday trading on Monday, reflecting strong positive investor sentiment.

The significant price movement follows the company's announcement that it received the U.S. Food and Drug Administration's fast track designation for zocilurtatug pelitecan, or zoci, for the treatment of extrapulmonary neuroendocrine carcinomas. This regulatory status is intended to expedite the review and development of new drugs that address an unmet medical need or treat serious or life-threatening diseases.

The fast track designation represents a key regulatory milestone that could potentially accelerate the path to market for this therapeutic candidate. Zoci had previously been granted fast track designation for the treatment of extensive-stage small cell lung cancer in May 2025, further highlighting the drug's development potential.